Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bronchial Diseases

ClinicalTrials.gov lists 6,261 trials for Bronchial Diseases or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 346.

MeSH D001982 Respiratory Tract Diseases C08
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 469 Phase 1/2 Phase 1/2 121 Phase 2 Phase 2 830 Phase 2/3 Phase 2/3 70 Phase 3 Phase 3 755 Phase 4 Phase 4 604 Not applicable Not applicable 1,724 Observational Observational 1,686 Phase 1 Phase 1 469 Phase 1/2 Phase 1/2 121 Phase 2 Phase 2 830 Phase 2/3 Phase 2/3 70 Phase 3 Phase 3 755 Phase 4 Phase 4 604 Not applicable Not applicable 1,724 Observational Observational 1,686

Trials per phase (log scale)

1 more section with rows

55 of the 6,261 trials are tagged with Bronchial Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Bronchial Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bronchial Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 8 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 315

1990: 10 trials (Observational 8, Not applicable 1, Phase 3 1) 1991: 5 trials (Observational 4, Phase 3 1) 1992: 7 trials (Observational 5, Not applicable 1, Phase 4 1) 1993: 6 trials (Observational 3, Phase 4 1, Phase 3 2) 1994: 8 trials (Observational 5, Not applicable 1, Phase 3 2) 1995: 6 trials (Observational 5, Phase 3 1) 1996: 11 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 2 1) 1997: 11 trials (Observational 5, Phase 4 1, Phase 3 3, Phase 2 2) 1998: 19 trials (Observational 5, Not applicable 3, Phase 4 5, Phase 3 5, Phase 2 1) 1999: 34 trials (Observational 18, Not applicable 6, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 3) 2000: 34 trials (Observational 17, Not applicable 4, Phase 4 4, Phase 3 7, Phase 2/3 1, Phase 1/2 1) 2001: 47 trials (Observational 13, Not applicable 12, Phase 4 3, Phase 3 9, Phase 2 7, Phase 1/2 2, Phase 1 1) 2002: 82 trials (Observational 8, Not applicable 16, Phase 4 14, Phase 3 32, Phase 2 10, Phase 1/2 1, Phase 1 1) 2003: 115 trials (Observational 11, Not applicable 29, Phase 4 23, Phase 3 34, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 1) 2004: 141 trials (Observational 27, Not applicable 31, Phase 4 24, Phase 3 37, Phase 2/3 2, Phase 2 14, Phase 1/2 1, Phase 1 5) 2005: 185 trials (Observational 41, Not applicable 29, Phase 4 31, Phase 3 41, Phase 2/3 4, Phase 2 24, Phase 1/2 2, Phase 1 13) 2006: 221 trials (Observational 38, Not applicable 49, Phase 4 36, Phase 3 38, Phase 2/3 8, Phase 2 33, Phase 1/2 7, Phase 1 12) 2007: 254 trials (Observational 72, Not applicable 37, Phase 4 47, Phase 3 37, Phase 2/3 2, Phase 2 37, Phase 1/2 3, Phase 1 19) 2008: 262 trials (Observational 55, Not applicable 52, Phase 4 28, Phase 3 28, Phase 2/3 3, Phase 2 62, Phase 1/2 6, Phase 1 28) 2009: 271 trials (Observational 77, Not applicable 56, Phase 4 26, Phase 3 25, Phase 2/3 6, Phase 2 55, Phase 1/2 6, Phase 1 20) 2010: 285 trials (Observational 62, Not applicable 51, Phase 4 31, Phase 3 30, Phase 2/3 7, Phase 2 60, Phase 1/2 8, Phase 1 36) 2011: 292 trials (Observational 78, Not applicable 66, Phase 4 28, Phase 3 38, Phase 2/3 2, Phase 2 49, Phase 1/2 6, Phase 1 25) 2012: 315 trials (Observational 67, Not applicable 82, Phase 4 25, Phase 3 41, Phase 2/3 4, Phase 2 62, Phase 1/2 7, Phase 1 27) 2013: 241 trials (Observational 49, Not applicable 65, Phase 4 24, Phase 3 31, Phase 2/3 3, Phase 2 38, Phase 1/2 6, Phase 1 25) 2014: 243 trials (Observational 44, Not applicable 76, Phase 4 27, Phase 3 38, Phase 2/3 4, Phase 2 26, Phase 1/2 6, Phase 1 22) 2015: 299 trials (Observational 77, Not applicable 96, Phase 4 19, Phase 3 37, Phase 2/3 5, Phase 2 42, Phase 1/2 2, Phase 1 21) 2016: 271 trials (Observational 59, Not applicable 101, Phase 4 27, Phase 3 19, Phase 2/3 1, Phase 2 28, Phase 1/2 8, Phase 1 28) 2017: 268 trials (Observational 80, Not applicable 78, Phase 4 19, Phase 3 29, Phase 2/3 3, Phase 2 32, Phase 1/2 6, Phase 1 21) 2018: 232 trials (Observational 71, Not applicable 72, Phase 4 19, Phase 3 32, Phase 2 20, Phase 1/2 3, Phase 1 15) 2019: 263 trials (Observational 80, Not applicable 83, Phase 4 17, Phase 3 28, Phase 2/3 1, Phase 2 21, Phase 1/2 8, Phase 1 25) 2020: 211 trials (Observational 87, Not applicable 62, Phase 4 13, Phase 3 12, Phase 2/3 2, Phase 2 19, Phase 1/2 5, Phase 1 11) 2021: 273 trials (Observational 99, Not applicable 71, Phase 4 26, Phase 3 15, Phase 2/3 3, Phase 2 28, Phase 1/2 4, Phase 1 27) 2022: 233 trials (Observational 74, Not applicable 81, Phase 4 12, Phase 3 17, Phase 2/3 2, Phase 2 24, Phase 1/2 5, Phase 1 18) 2023: 283 trials (Observational 92, Not applicable 112, Phase 4 15, Phase 3 19, Phase 2/3 2, Phase 2 24, Phase 1/2 5, Phase 1 14) 2024: 298 trials (Observational 98, Not applicable 109, Phase 4 23, Phase 3 21, Phase 2/3 1, Phase 2 25, Phase 1/2 3, Phase 1 18) 2025: 265 trials (Observational 84, Not applicable 88, Phase 4 11, Phase 3 21, Phase 2/3 1, Phase 2 37, Phase 1/2 4, Phase 1 19)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 207
2025 265
2024 298
2023 283
2022 233
2021 273
2020 211
2019 263
2018 232
2017 268

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 250 trials starting in 2026 and about 260 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 346 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 4,291 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bronchial Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 469
Phase 1/2 121
Phase 2 830
Phase 2/3 70
Phase 3 755
Phase 4 604
Not applicable 1,724
Observational 1,686
Expanded access 2

How many Bronchial Diseases trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 154
Recruiting 485
Enrolling by invitation 33
Active, not recruiting 162
Completed 4,078

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bronchial Diseases trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 346
GlaxoSmithKline 280
Novartis Pharmaceuticals 94
National Heart, Lung, and Blood Institute (NHLBI) 85
Organon and Co 69

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Bronchial Diseases? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Montelukast 123
OPN-375 99
Albuterol 59
Formoterol 41

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Budesonide EC 68
Drug: Omalizumab 68
Mepolizumab SC 48
Benralizumab Arm B 45
Formoterol-budesonide 43

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bronchial Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Invasive cancer of any type 4,851 1
Asthma 3,001 245
Major cardiovascular event 2,415 1
Hospitalizations 2,346 2
Gastrointestinal bleeding 2,232 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bronchial Diseases? (75)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. The Lancet. Respiratory medicine 2020 Yes
Rheological analysis of sputum from patients with chronic bronchial diseases. Scientific reports 2020 Yes
Association of Obesity with Quantitative Chest CT Measured Airway Wall Thickness in WTC Workers with Lower Airway Disease. Lung 2019 Yes
Flexible endoscopy for pediatric tracheobronchial metallic stent placement, maintenance and long-term outcomes. PloS one 2018 Yes
Self-expandable metallic stents in nonmalignant large airway disease. Canadian respiratory journal 2015 Yes

Showing 5 of 75 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages